Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced the commencement of a proposed underwritten public offering of approximately $100,000,000 of shares of its common stock.
May 11, 2020
· 3 min read